BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 1074 | Download: 987
 |
Received |
|
2014-01-04 14:24 |
 |
Peer-Review Started |
|
2014-01-04 19:26 |
 |
To Make the First Decision |
|
2014-02-13 16:04 |
 |
Return for Revision |
|
2014-02-20 20:38 |
 |
Revised |
|
2014-03-10 21:40 |
 |
Second Decision |
|
2014-06-16 13:56 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-06-16 14:06 |
 |
Articles in Press |
|
2014-06-16 14:43 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-07-24 14:16 |
 |
Publish the Manuscript Online |
|
2014-08-01 16:16 |
Category |
Biology |
Manuscript Type |
Topic Highlights |
Article Title |
C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
|
Manuscript Source |
Invited Manuscript |
All Author List |
Benedikte Jacobsen, Mette Camilla Kriegbaum, Eric Santoni-Rugiu and Michael Ploug |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Copenhagen University Hospital (Rigshospitalets Forskningspuljer) |
|
he Danish National Research Foundation (Danish-Chinese Centre for Proteases and Cancer) |
|
Harboefonden, Torben og Alice Frimodts Fond |
|
Fabrikant Einar Willumsens Mindelegat |
|
Holger Rabitz and hustrus Legat |
|
Lundbeck Foundation |
|
|
Corresponding Author |
Michael Ploug, PhD, DSc, The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maal?es Vej 5, Room 3.3.31, 2200 Copenhagen, Denmark. m-ploug@finsenlab.dk |
Key Words |
LYPD3; Non-small cell lung cancer; Prognosis; Solid growth pattern; Liver kinase B1; Precursor lesions; Atypical adenomatous hyperplasia; Metaplasia; Squamous differentiation; Ly6/Urokinase-type plasminogen activator receptor |
Core Tip |
C4.4A is a new biomarker with potential prognostic value in pulmonary adenocarcinoma. High levels of protein expression correlate with poor patient survival and a histological growth pattern of the solid type. Recent data suggest that C4.4A is negatively regulated by the tumor suppressor liver kinase B1 (LKB1), which is inactivated in a fraction of adenocarcinomas of the lung. Such an inverse association between C4.4A and LKB1 could possibly render C4.4A a candidate predictive biomarker for therapeutic intervention targeting components of the LKB1 pathway, such as mammalian target of rapamycin. |
Publish Date |
2014-08-01 16:16 |
Citation |
Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M. C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World J Clin Oncol 2014; 5(4): 621-632 |
URL |
http://www.wjgnet.com/2218-4333/full/v5/i4/621.htm |
DOI |
http://dx.doi.org/10.5306/wjco.v5.i4.621 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345